To date, in contrast to their success in treatment of non-central nervous system (CNS) cancers, none of immunotherapies has been demonstrated a successful treatment modality in CNS tumors, indicating a fundamental difference between CNS and peripheral cancer immune regulation. Novel diagnostic and therapeutic approaches tailored for CNS tumors need to be developed.
Here, identification of the key elements of the unique CNS tumor immune regulation is of great essence for: 1) development of next generation CNS tumor immunotherapies; 2) discovery of biomarkers in both CNS tumor diagnosis and assessment of immunotherapeutic efficacy; 3) combination of immunotherapies with other CNS tumor treatment strategies. In this essence, emerging glioma theranostic approaches, such as tumor treatment field (TTF), macrophage cell- and apoptotic cell-targeted therapies as well as exosome diagnostics, represent newly unchartered territories awaiting extensive investigations in neuro-immuno-oncology. In addition to CNS tumor-focused studies, comparative studies investigating peripheral and CNS immunology under both tumoral and non-tumoral conditions will also provide important knowledge in our understanding of CNS tumor immune resistance.
We welcome both Original Research and Review articles within the scope of the Research Topic. Studies address following key points are of great interest under this the Research Topic.
- Identification of novel, unique biomarker that will contribute to diagnostic, prognostic or predictive biomarkers for immunological aberration in gliomas and brain metastatic tumors
- Advancements in the understanding of the role of single-cell sequencing for better understanding of neuro-immunology in gliomas, especially in glioblastoma
- Exploration of novel functions of macrophages within the tumor immune microenvironment, especially tumor-macrophage interactions
-Novel therapeutic approaches to target both tumor and macrophages with gene-editing, nanoparticles and small molecules.
Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo), as well as those where experimental validation is restricted to cell lines only, are out of scope for this section.
To date, in contrast to their success in treatment of non-central nervous system (CNS) cancers, none of immunotherapies has been demonstrated a successful treatment modality in CNS tumors, indicating a fundamental difference between CNS and peripheral cancer immune regulation. Novel diagnostic and therapeutic approaches tailored for CNS tumors need to be developed.
Here, identification of the key elements of the unique CNS tumor immune regulation is of great essence for: 1) development of next generation CNS tumor immunotherapies; 2) discovery of biomarkers in both CNS tumor diagnosis and assessment of immunotherapeutic efficacy; 3) combination of immunotherapies with other CNS tumor treatment strategies. In this essence, emerging glioma theranostic approaches, such as tumor treatment field (TTF), macrophage cell- and apoptotic cell-targeted therapies as well as exosome diagnostics, represent newly unchartered territories awaiting extensive investigations in neuro-immuno-oncology. In addition to CNS tumor-focused studies, comparative studies investigating peripheral and CNS immunology under both tumoral and non-tumoral conditions will also provide important knowledge in our understanding of CNS tumor immune resistance.
We welcome both Original Research and Review articles within the scope of the Research Topic. Studies address following key points are of great interest under this the Research Topic.
- Identification of novel, unique biomarker that will contribute to diagnostic, prognostic or predictive biomarkers for immunological aberration in gliomas and brain metastatic tumors
- Advancements in the understanding of the role of single-cell sequencing for better understanding of neuro-immunology in gliomas, especially in glioblastoma
- Exploration of novel functions of macrophages within the tumor immune microenvironment, especially tumor-macrophage interactions
-Novel therapeutic approaches to target both tumor and macrophages with gene-editing, nanoparticles and small molecules.
Note: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo), as well as those where experimental validation is restricted to cell lines only, are out of scope for this section.
